Assenagon Asset Management
RXRX icon

Assenagon Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Assenagon Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,179
Closed -$73K – 1569
2022
Q1 		$73K Hold
10,179
– – ﹤0.01% 1387
2021
Q4 		$174K Buy
+10,179
New +$192K ﹤0.01% 1384

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Assenagon Asset Management's RXRX Position: Q2 2022 in Review

Assenagon Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2022, closing a stake of 10,179 shares — an estimated $73K sold.

Assenagon Asset Management first reported a position in RXRX in Q4 2021 and held it in 2 quarters. The position peaked at $174K in Q4 2021. 133 funds tracked by Wall St. Rank hold RXRX as of Q2 2022.

  • Assenagon Asset Management reported no remaining Recursion Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Assenagon Asset Management sold 10,179 Recursion Pharmaceuticals shares in Q2 2022, an estimated $73K.
  • Assenagon Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Assenagon Asset Management's Recursion Pharmaceuticals position peaked at $174K in Q4 2021.
  • 133 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2022.

Based on Assenagon Asset Management's 13F filing for Q2 2022, filed 27 Jul 2022.